EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 184 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $221 | +317.0% | 42,039 | +1443.8% | 0.00% | – |
| Q2 2023 | $53 | -31.2% | 2,723 | 0.0% | 0.00% | – |
| Q1 2023 | $77 | -3.8% | 2,723 | 0.0% | 0.00% | – |
| Q4 2022 | $80 | -99.9% | 2,723 | 0.0% | 0.00% | – |
| Q3 2022 | $72,000 | -40.5% | 2,723 | 0.0% | 0.00% | -100.0% |
| Q2 2022 | $121,000 | -10.4% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $135,000 | -2.9% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $139,000 | -8.6% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $152,000 | +29.9% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $117,000 | +2.6% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $114,000 | -10.2% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $127,000 | +9.5% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $116,000 | -11.5% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $131,000 | +4.8% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $125,000 | -23.8% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $164,000 | +6.5% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $154,000 | +1.3% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $152,000 | +10.9% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $137,000 | +24.5% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $110,000 | -41.8% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $189,000 | -8.3% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $206,000 | +44.1% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $143,000 | -1.4% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $145,000 | -10.5% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $162,000 | -24.7% | 2,723 | 0.0% | 0.00% | -50.0% |
| Q2 2017 | $215,000 | -4.9% | 2,723 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $226,000 | -1.7% | 2,723 | -6.2% | 0.00% | 0.0% |
| Q4 2016 | $230,000 | +12.2% | 2,902 | -0.8% | 0.00% | 0.0% |
| Q3 2016 | $205,000 | +81.4% | 2,926 | 0.0% | 0.00% | +100.0% |
| Q2 2016 | $113,000 | -5.0% | 2,926 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $119,000 | -38.7% | 2,926 | +33.9% | 0.00% | -50.0% |
| Q4 2015 | $194,000 | +19.8% | 2,185 | 0.0% | 0.00% | +100.0% |
| Q3 2015 | $162,000 | -8.5% | 2,185 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $177,000 | – | 2,185 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |